Bruin Biometrics LLC (BBI), has agreed for Arjo (ARJO-B.ST), a market-leading supplier of medical devices and solutions, to acquire an equity stake in Bruin Biometrics. Arjo is appointed an exclusive distributor for BBI’s pressure ulcer assessment device, the SEM Scanner.
BBI is a US-based technology company committed to modernizing health care with biometric sensor technology for the early detection and monitoring of chronic, preventable conditions in collaboration with clinicians.
NHSI1 report that in the UK between 1700-2000 patients develop a pressure injury/ulcer per month and that treating pressure ulcers costs the NHS more than £3.8m per month. Whilst in the US 2.5million patients develop a pressure injury/ulcer per year2 costing the US health system $26.8billion.3
“The BBI technology is well aligned with our strategy and will help us strengthen our offering of outcome-based solutions. By combining our extensive knowledge and sales network with BBI’s technology, we will help drive a shift in pressure injury management towards prevention and ultimately better clinical and financial outcomes,” says Joacim Lindoff, President & CEO of Arjo. “This investment means we will gain further access to the wound care market, where we see substantial growth potential,” adds Lindoff.
“Few medical conditions ever present themselves to an attainable and near-term preventative solution as pressure injuries. Realizing the outcome of preventing preventable pressure injuries benefits millions of patients affected and tens of thousands who die from related complications every year. Economic savings through prevention extend to many tens of billions of dollars annually”, says Martin Burns, CEO of BBI. “Pressure injury incidence can and should be reduced. Arjo’s knowledge, expertise and scale will enable many patients and their families, providers, and payors to benefit from this solution worldwide,” adds Burns.
Provizio® SEM Scanner, is the first hand-held wireless scanner with intelligence inside, for fast and easy pressure injury/ulcer risk assessments and the only SEM Scanner that acts as an adjunct to routine clinical skin assessment on the sacrum and heels. Digitally enhancing the patient care pathway with built-in data transfer for enhanced insight and risk identification, on admission and five days* earlier than visual skin assessment,4 regardless of skin tone.5 In clinical practice since 2014, the new Provizio SEM Scanner has, in preliminary laboratory testing, shown the same precision as the previous SEM Scanner 200 model.6
Martin Burns also commented that “In collaboration with our clinical partners and expert researchers from all over the world, BBI has helped define and advance the prevention of pressure ulcers/injuries with BBI’s work extending well beyond the development and commercialization of our SEM Scanner and now Provizio SEM Scanner. To achieve prevention, nurses need to know how to use the device in the care pathway, on which patients, when, and how to act when they record abnormal measures. All of that clinical implementation research work has now been completed in acute, post-acute and community care settings. Arjo represent an ideal partner for BBI; they understand prevention and are vigorously helping their clinical customers achieve the clinical outcome of full prevention and cost savings from prevention. Their platform extends from acute to post-acute care, globally, and we are delighted to be extending our working relationship with them”.
The Distribution Agreement commenced as signed on October 8 2020 .
For further information, please contact:
Kate Hancock, Global VP Marketing and Clinical Communications
Tel: +44 7827 315347
Executive Vice President, Marketing Communications & Public Relations
Telephone: +46 (0)10 335 4810
Investor Relations & Corporate Communications
Telephone: +46 (0)10 335 4866
Have questions about our company, products or pipeline? We'd like to hear from you.